0000950170-24-051488.txt : 20240501 0000950170-24-051488.hdr.sgml : 20240501 20240501193634 ACCESSION NUMBER: 0000950170-24-051488 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240429 FILED AS OF DATE: 20240501 DATE AS OF CHANGE: 20240501 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gangloff Scott A. CENTRAL INDEX KEY: 0001663253 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38944 FILM NUMBER: 24904693 MAIL ADDRESS: STREET 1: C/O ONCOBIOLOGICS, INC. STREET 2: 7 CLARKE DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Akero Therapeutics, Inc. CENTRAL INDEX KEY: 0001744659 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 601 GATEWAY BOULEVARD, SUITE 350 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-487-6488 MAIL ADDRESS: STREET 1: 601 GATEWAY BOULEVARD, SUITE 350 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 ownership.xml 4 X0508 4 2024-04-29 0001744659 Akero Therapeutics, Inc. AKRO 0001663253 Gangloff Scott A. C/O AKERO THERAPEUTICS, INC. 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080 false true false false Chief Technology Officer false Stock Option (Right to Buy) 19.62 2024-04-29 4 A false 225000 0.00 A 2034-04-28 Common Stock 225000 225000 D Twenty-five (25) percent of the shares subject to this option shall vest and become exercisable on April 29, 2025, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. /s/ Jonathan Young, Attorney-in-fact 2024-05-01